Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to analysts. On December 19, TheFly reported that Cathie Wood’s ARK Investment has ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Some investors closely monitor the portfolios of billionaires to get ideas. Another approach, however, is to examine the stocks held by highly successful companies. Recursion looks like a big dud so ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. The analyst who called NVIDIA in 2010 just named his top ...

The overall stock market decline likely weighed on Recursion's shares. CNBC host Jim Cramer's recent hesitation about the biotech stock could also be causing angst for investors. Part of the reason ...